Hegi, Monika E.

MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma

Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine

Glioma Diagnosis and TreatmentPARP inhibition in cancer therapy

Cited by 7,405

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial

Stupp, R., Taillibert, S., Kanner, A., Read, W., Steinberg, D. M., Lhermitte, B., Toms, S., Idbaih, A., Ahluwalia, M. S., Fink, K., et al. (2017) · JAMA

Glioma Diagnosis and TreatmentElectromagnetic Fields and Biological Effects

Cited by 2,644

EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood

Weller, M., van den Bent, M., Preusser, M., Le Rhun, E., Tonn, J. C., Minniti, G., Bendszus, M., Balana, C., Chinot, O., Dirven, L., et al. (2021) · Nature Reviews Clinical Oncology

Glioma Diagnosis and TreatmentAdvanced Neuroimaging Techniques and Applications

Cited by 2,048

Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial

Stupp, R., Taillibert, S., Kanner, A. A., Kesari, S., Steinberg, D. M., Toms, S. A., Taylor, L. P., Lieberman, F., Silvani, A., Fink, K. L., et al. (2015) · JAMA

Glioma Diagnosis and TreatmentMathematical Biology Tumor Growth

Cited by 1,259

Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions

Wen, P. Y., Weller, M., Lee, E. Q., Alexander, B. M., Barnholtz-Sloan, J. S., Barthel, F. P., Batchelor, T. T., Bindra, R. S., Chang, S. M., Chiocca, E. A., et al. (2020) · Neuro-Oncology

Glioma Diagnosis and TreatmentOvarian cancer diagnosis and treatment

Cited by 1,168

Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial

Gilbert, M. R., Wang, M., Aldape, K. D., Stupp, R., Hegi, M. E., Jaeckle, K. A., Armstrong, T. S., Wefel, J. S., Won, M., Blumenthal, D. T., et al. (2013) · Journal of Clinical Oncology

Glioma Diagnosis and TreatmentPARP inhibition in cancer therapy

Cited by 1,063

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

Stupp, R., Hegi, M. E., Gorlia, T., Erridge, S. C., Perry, J., Hong, Y.-K., Aldape, K. D., Lhermitte, B., Pietsch, T., Grujicic, D., et al. (2014) · The Lancet Oncology

Glioma Diagnosis and TreatmentPARP inhibition in cancer therapy

Cited by 1,052

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

Baumert, B. G., Hegi, M. E., van den Bent, M. J., von Deimling, A., Gorlia, T., Hoang-Xuan, K., Brandes, A. A., Kantor, G., Taphoorn, M. J. B., Hassel, M. B., et al. (2016) · The Lancet Oncology

Glioma Diagnosis and TreatmentAcute Myeloid Leukemia Research

Cited by 495

p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma

Fulci, G., Labuhn, M., Maier, D., Lachat, Y., Hausmann, O., Hegi, M. E., Janzer, R. C., Merlo, A., & Van Meir, E. G. (2000) · Oncogene

Cancer-related Molecular PathwaysGlioma Diagnosis and Treatment

Cited by 146

DNA fingerprinting of glioma cell lines and considerations on similarity measurements

Bady, P., Diserens, A.-C., Castella, V., Kalt, S., Heinimann, K., Hamou, M.-F., Delorenzi, M., & Hegi, M. E. (2012) · Neuro-Oncology

Glioma Diagnosis and TreatmentGenetic diversity and population structure

Cited by 57